Cantor Fitzgerald Predicts Krystal Biotech FY2026 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Krystal Biotech in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of $7.65 for the year. Cantor Fitzgerald has a "Overweight" rating and a $215.00 price objective on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%.

Other equities research analysts also recently issued reports about the stock. Chardan Capital reiterated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Wednesday, May 7th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. Citigroup cut their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of "Buy" and an average target price of $211.13.

Krystal Biotech Price Performance

NASDAQ:KRYS traded up $2.13 during mid-day trading on Tuesday, reaching $138.21. The company's stock had a trading volume of 240,919 shares, compared to its average volume of 311,880. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $219.34. The company's fifty day simple moving average is $148.95 and its two-hundred day simple moving average is $162.61. The stock has a market cap of $3.99 billion, a P/E ratio of 46.22 and a beta of 0.65.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in KRYS. FMR LLC grew its holdings in shares of Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. lifted its position in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC lifted its position in Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after purchasing an additional 6,600 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after buying an additional 365,304 shares in the last quarter. Finally, Hood River Capital Management LLC boosted its stake in Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock worth $80,324,000 after buying an additional 10,622 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).